
zzso a potent and selective second-generation inhibitor of vascular zzso growth factor zzso enhanced the efficacy of chemotherapy in human zzso zzso zzso This phase I study investigated the safety, zzso zzso and zzso activity of zzso combined with zzso 

A total of 42 patients with advanced solid zzso received a continuous zzso starting dose of 5 zzso twice daily zzso plus zzso (90 zzso zzso zzso zzso zzso zzso zzso every 3 weeks) or zzso zzso or zzso zzso zzso zzso days zzso 

Common zzso adverse events across all zzso were zzso zzso hypertension zzso fatigue zzso zzso zzso decreased appetite zzso and zzso syndrome zzso There was one complete response, nine partial responses and seven patients with stable zzso Ten patients zzso remained on therapy for zzso zzso zzso and zzso zzso were similar in the absence or presence of zzso but zzso exposure was increased in the presence of zzso zzso zzso were similar in the absence or presence of zzso zzso 

zzso combined with zzso or zzso was well zzso no additive increase in zzso was zzso zzso activity was observed for each treatment regimen and across multiple zzso zzso 

